Protective antibody responses to influenza A/H1N1/09 vaccination in children with celiac disease

Area of Science:

• Immunology
• Pediatrics
• Infectious Diseases

Background:

• Celiac disease patients face higher risks of severe influenza infections.
• Impaired immune responses to some vaccines are noted in celiac disease.
• Influenza A/H1N1/09 pandemic necessitated evaluating vaccine efficacy in vulnerable groups.

Purpose of the Study:

• To assess pandemic influenza A/H1N1/09 vaccine responses in pediatric celiac disease patients.
• To compare antibody titers in celiac disease patients with age- and sex-matched controls.

Main Methods:

• Prospective investigation of 14 pediatric celiac disease patients.
• Age- and sex-matching with a control group of healthy children.
• Measurement of pandemic vaccine antibody titers post-vaccination.

Main Results:

• All pediatric patients with celiac disease achieved protective antibody titers (≥40).
• Geometric mean titers were comparable between celiac disease patients (530) and controls (573).
• No significant difference in vaccine response was observed between the groups.

Conclusions:

• Pediatric patients with celiac disease demonstrate robust antibody responses to the pandemic influenza A/H1N1/09 vaccine.
• The findings suggest comparable vaccine effectiveness in celiac disease patients and healthy children.
• This supports routine influenza vaccination recommendations for children with celiac disease.